Genzyme has rejected Sanofi-Aventis $18.5bn (€14.5bn) takeover bid, describing it as offering no improvement in price on the previous proposal and failing “to establish a basis for engagement.”
Created by DNMPharma2 on 27/02/2009
Last updated: 31/08/10 at 15:09
Tags: Genzyme Sanofi Aventis
Sanofi Aventis has gone public with its $18.5bn (€14.5bn) takeover bid for US biotech Genzyme, putting more pressure on firm’s “unwilling” board
http://www.in-pharmatechnologist.com/Industry-Drivers/Sanofi-goes-public-on-18.5bn-bid-for-unwilling-Genzyme
http://www.in-pharmatechnologist.com/Industry-Drivers/EU-majors-reported-to-be-looking-at-Genzyme
Rumour has it that French drug giant Sanofi Aventis is planning to make a $20bn (€16bn) acquisition in the US with speculation that biotechs like Allergan, Biogen Idec and Genzyme are among the targets.
http://www.in-pharmatechnologist.com/Industry-Drivers/Sanofi-said-to-be-planning-20bn-acquisition-in-US
US biotech Genzyme will pay $175m and cease some manufacturing operations at its facility in Allston, Massachusetts under final terms of Food and Drug Administration (FDA) consent decree.
http://www.in-pharmatechnologist.com/Processing-QC/175m-fine-for-Genzyme-after-Allston-troubles
Genzyme and Arecor have entered into a collaboration to develop advanced formulations for protein therapeutics.
http://www.in-pharmatechnologist.com/Materials-Formulation/Genzyme-and-Arecor-collaborate-on-protein-formulation
Genzyme receives US Food and Drug Administration (FDA) “consent decree” for troubled Allston manufacturing plant.
http://www.in-pharmatechnologist.com/Industry-Drivers/US-FDA-to-oversee-ops-at-Genzyme-s-Allston-plant
US drugmaker Genzyme has detected an impurity in one vial of the Gaucher’s disease drug Cerezyme produced at its manufacturing facility in Waterford, Ireland.
http://www.in-pharmatechnologist.com/Processing-QC/Genzyme-addresses-impurity-problem-at-Ireland-Cerezyme-plant
Changes to manufacturing practices at Genzyme’s plant have led to further shortages of Fabrazyme (agalsidase beta), with production expected to remain below 30 per cent of demand until after June 30.
http://www.in-pharmatechnologist.com/Processing-QC/Manufacturing-changes-extend-Genzyme-s-Fabrazyme-shortage
Genzyme has reported a small dip in preliminary fourth quarter and full year revenues, driven by declining sales of Cerezyme and Fabrazyme which have been affected by manufacturing problems.
http://www.in-pharmatechnologist.com/Processing-QC/Genzyme-s-preliminary-revenues-dip
Genzyme is outsourcing fill and finish manufacturing of several major drugs to Hospira in response to in-house difficulties at its Allston Landing facility in Boston, Massachusetts, US.
http://www.in-pharmatechnologist.com/Processing-QC/Genzyme-outsources-to-Hospira-following-in-house-problems
Pfizer and Protalix have increased the pressure on Genzyme by signing a new accord to commercialise Uplyso (taliglucerase alfa), a potential rival to its Gaucher’s disease treatment Cerezyme, just days after the US biotech resumed production.
http://www.in-pharmatechnologist.com/Processing-QC/Genzyme-ships-Cerezyme-again-Pfizer-licenses-Protalix-rival
US FDA maintains market approval for key Genzyme drugs despite reports of steel and rubber fragments in some batches.
http://www.in-pharmatechnologist.com/Processing-QC/Contamination-found-in-Genzyme-drugs-no-FDA-ban
US biotechnology major Genzyme has begun $68m of refurbishment work on a new 211,000 sgft manufacturing and shipping complex in Northborough, Massachusetts.
http://www.in-pharmatechnologist.com/Industry-Drivers/Genzyme-starts-work-on-new-Mass-facility
The EMEA has issued US biotech firm Genzyme with a letter detailing “one major observation and several other observations” following an inspection of its Allston, Massachusetts manufacturing plant last month.
http://www.in-pharmatechnologist.com/Industry-Drivers/Genzyme-receives-EMEA-letter-about-Allston-plant
Shareholders have filed an $8bn (€5.7bn) lawsuit against Genzyme alleging that the company’s CEO “issued a series of materially false and misleading statements” about its manufacturing problems.
http://www.in-pharmatechnologist.com/Processing-QC/Genzyme-hit-with-8bn-lawsuit
The FDA has found “significant objectionable conditions” at the Genzyme manufacturing facility that makes Lumizyme, creating another issue in the product’s approval process.
http://www.in-pharmatechnologist.com/Processing-QC/Genzyme-accused-of-cGMP-deficiencies-by-FDA
Update Sources